FDA approves perampanel as adjunctive treatment for partial-onset seizures in patients with epilepsy aged 12 years and older


FDA has approved perampanel (Fycompa, Eisai), an AMPA receptor antagonist, as an adjunctive treatment of partial-onset seizures with or without secondarily generalized seizures in patients aged 12 years and older who have epilepsy.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.